Compare Gilead Sciences, Inc. (GILD) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? Gilead Sciences, Inc. trades at $135.94 (market cap $168.35B), while Vanguard International High Dividend Yield ETF trades at $104.46. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VYMI | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $105.05 |
52-Week Low | $110.56 | $82.92 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
VYMI trades at $104.69, up 0.1% on the day, with strong technical momentum as it approaches resistance at $105. The ETF has gained attention for its international dividend strategy, offering a 3.4% yield and delivering 55% total returns since previous coverage. Recent institutional buying and positive media sentiment highlight growing investor interest in international high-yield exposure.
The outlook remains positive given Vanguard's projection of international developed-market stocks outperforming US markets over the next decade. Key opportunities include diversification benefits and strong dividend growth, while risks center on currency fluctuations and global economic volatility. The ETF's technical strength and fundamental appeal support a constructive view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
